Magnetar Financial LLC purchased a new stake in Glaukos Co. (NYSE:GKOS – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 24,798 shares of the medical instruments supplier’s stock, valued at approximately $2,338,000.
Several other institutional investors and hedge funds have also modified their holdings of GKOS. National Bank of Canada FI acquired a new stake in Glaukos during the fourth quarter worth about $46,000. GAMMA Investing LLC acquired a new stake in Glaukos during the fourth quarter worth about $55,000. Quadrant Capital Group LLC grew its stake in Glaukos by 54.8% during the fourth quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock worth $74,000 after buying an additional 329 shares in the last quarter. Caldwell Sutter Capital Inc. grew its stake in Glaukos by 5,860.0% during the first quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock worth $140,000 after buying an additional 1,465 shares in the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new stake in shares of Glaukos in the 1st quarter valued at approximately $217,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.
Glaukos Price Performance
Glaukos stock traded up $2.17 during mid-day trading on Friday, hitting $119.82. 617,615 shares of the company traded hands, compared to its average volume of 570,732. Glaukos Co. has a one year low of $59.22 and a one year high of $126.96. The company has a current ratio of 5.38, a quick ratio of 4.68 and a debt-to-equity ratio of 0.78. The stock has a fifty day moving average price of $115.88 and a 200-day moving average price of $101.88.
Insider Buying and Selling
In other Glaukos news, COO Joseph E. Gilliam sold 2,059 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $105.52, for a total transaction of $217,265.68. Following the transaction, the chief operating officer now directly owns 101,845 shares of the company’s stock, valued at approximately $10,746,684.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, COO Joseph E. Gilliam sold 2,059 shares of the company’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $105.52, for a total value of $217,265.68. Following the sale, the chief operating officer now directly owns 101,845 shares of the company’s stock, valued at approximately $10,746,684.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Alex R. Thurman sold 442 shares of the company’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $105.69, for a total transaction of $46,714.98. Following the completion of the transaction, the chief financial officer now owns 52,090 shares in the company, valued at approximately $5,505,392.10. The disclosure for this sale can be found here. Insiders have sold a total of 21,444 shares of company stock valued at $2,411,171 over the last three months. 6.40% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on GKOS. Wells Fargo & Company raised their price target on shares of Glaukos from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Monday, June 3rd. JPMorgan Chase & Co. increased their target price on shares of Glaukos from $108.00 to $110.00 and gave the stock an “overweight” rating in a research note on Thursday, May 2nd. Mizuho raised their price objective on shares of Glaukos from $85.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Needham & Company LLC raised their price objective on shares of Glaukos from $108.00 to $113.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. Finally, Morgan Stanley raised their price objective on shares of Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $120.64.
View Our Latest Stock Analysis on Glaukos
Glaukos Company Profile
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Featured Articles
- Five stocks we like better than Glaukos
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Compound Interest and Why It Matters When Investing
- Why Call Options Volume for These 2 Stocks Spiked Together
- The 3 Best Fintech Stocks to Buy Now
- MarketBeat Week in Review – 7/22 – 7/26
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Co. (NYSE:GKOS – Free Report).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.